Submitting Abstracts

The Organizing Committee invites you to actively participate in this congress which will be an extraordinary occasion for the exchange of thoughts and experiences. We look forward to receiving abstracts for oral and poster presentations.

Abstracts submission deadline extended until 12th May 2019.

How to submit

Abstracts must be submitted via on-line. You must be registered to submit an abstract.

  • You will find the access to the abstracts sumbission plattform on the receipt of your registration.
  • Once the abstract has been uploaded successfully a confirmation email will be sent to the corresponding author. In case that a confirmation e-mail is not received after 24 hours, please check your spam folder. If indeed you have not received it, please contact: emchd2019-abs@kenes.com
  • Authors will have access to their submitted abstracts and will have the possibility to edit them until the abstracts’ submission deadline.
  • All correspondence concerning the abstract will be sent to the corresponding author.

Abstract Submission Instructions

  • Each abstract should represent new data that have neither been published nor presented elsewhere before the submission date of 12th May, 2019.
  • Abstracts will be published in the Molecular Immunology and must be written in American or British English.
  • Authors will be asked to select the topic when the abstract is submitted, but the congress organisers reserve the right to re-allocate the abstract to a different topic if it is felt to be more appropriate.
  • The contributors should indicate the presentation preference (oral and/or poster).

Abstract Instructions

Please do type the TITLE in CAPITAL LETTERS. Use succinct and descriptive words in your title. Attendees often are attracted to your poster by reading your title. Do not indent any lines of the title. Do not use abbreviations in the title.

  • The abstract should be informative, containing:

– The specific objectives of the study.
– A brief statement of method, if pertinent.
– A summary of the main results.
– A conclusion containing the main message of the paper. (It is not acceptable to state, for instance: «our data concerning. will be presented» or «The results will be discussed».)
– Figures, images, or tables of any kind are not permitted.

  • There is a maximum 400 words for the Abstract (including Title, Authors, Institutions, Body, including acknowledgements of support).
  • Type the entire abstract text in one paragraph, single-spaced, and left-justified. There should be no indents or spaces (i.e. no margins or spaces before or after the paragraph).
  • Either type directly or copy your finished abstract into the text boxes. If formatted text is inserted from a word processing program into the fields, please note that some formatting might get lost. Special characters like α, β or superscripted or subscript characters in chemical expression like H2O can be transferred erroneously.
  • When using non-standard abbreviations, spell them out in full the first time they appear in the text followed by the abbreviations in parentheses. Capitalize the first letter of trade names.
  • The formatting of the presenting author, the other authors and their institutional addresses is done automatically. So please do NOT enter it in the main abstract text field.
  • Do not forget to indicate a scientific topic that you think fit best with your abstract.

Disclosures

  • You must complete a Disclosure Form on-line for all submitted abstracts and disclose any potential conflict of interest (COI), including but not limited to financial relationships with commercial entities (research sponsorship, royalties, ownership of stock or stock options, employment, paid consultancy, non-remunerative positions of influence and others) that may influence the presentation of data. The limit of time of a relevant relationship is inclusive of the last 12 months.
  • Abstracts will not be accepted without proper completion of the Disclosure Form.
  • Authors should disclose in their presentations, as a separate second slide in an oral presentation, or a statement in a poster presentation in the bottom left corner, the relevant COI. In case of no relevant COI, the second slide and poster presentation should state: ‘No relevant conflicts of interest to disclose’.

Abstract Review

All contributions to the EMCHD- 2019 will require the submission of an abstract, and a rigorous review procedure will be undertaken to maintain the highest scientific quality of the congress. All submitted abstracts will be reviewed according to the following criteria:

  • The work makes a significant and original contribution to the field.
  • The scientific content falls within the scientific scope of the meeting.
  • The abstract complies with the submission instructions.

A score will be assigned based on the following assessment criteria for scientific content:

  • 5 – Ground breaking research of outstanding quality and vision in the field.
  • 4 – An innovative perspective on current understanding; high quality research providing new insights; a major development in the field; the exploitation of new scientific and health-care developments, unreported in the Complement field; advancing our understanding of Complement field.
  • 3 – An interesting and important addition, helping the continued development of the field.
  • 2 – A modest addition to the field, contributing to the development of a specific area.
  • 1 – Work demonstrating little scientific innovation over and above current published work; lacking scientific data, argument or foundation.

The organizing committee will collect all scores, combine them into a single document and calculate the mean value. Highest-ranking scores within each category will be selected for oral presentation (if the authors chose oral presentation as their preference).

The reviewers will also take the following matters into consideration in their assessment of the abstract:

  • The abstract is written in clear and acceptable English with few syntax and spelling mistakes.
  • The abstract follows the guidelines in terms of content and format.
  • Sufficient data is clearly presented and/or analyzed, is adequately discussed and appropriate conclusions drawn.

Failure to comply with these simple guidelines will affect the assessment score and may result in the rejection of an abstract.

Awards

The ECN and EMCHD2019-LOC will provide as many awards as possible to qualified young investigators. Travel awards will be selected on the basis of abstract scoring by the Council.

Elegibility

  • Undergraduate or graduate student and postdoctoral fellow not longer than five years after the PhD/MD or equivalent,
  • Must be registered for the EMCHD2019 and submit an abstract,
  • Must be the first author of a submitted abstract and must personally present the work at the workshop, either in a form of an oral presentation or a poster

When to apply

Submission of Travel Award applications will be available once the abstracts have been accepted for presentation (either oral or poster) and will be communicated with the abstract´s acceptance letters.

Documents Required

  • A letter from the nominee’s supervisor, which attests to the nominee’s role in the work and trainee status, and comments on the potential of the nominee as a biomedical research investigator.
  • Abstract number(s) – Please make note of your abstract number(s) once submitted to put on this travel award application.

Please note – individuals with a faculty appointment are not eligible for these awards.

Dates to remember

Deadlines
1st April 2019 Opening for abstract submission
12th May 2019 Deadline for abstract submission
3rd July 2019 Registration early bird deadline
July 2019 Notification of abstract acceptance and presentation type (oral/poster)

Abstract topics

  • Complement structure and function
  • Complement crosstalk
  • Complement therapies
  • Infection and autoimmunity
  • Complement genetics
  • Complement related diseases
  • Animal models

Poster board size

Available space on the poster board, for each poster, will be 90 cm in width (horizontally) and 120cm in height (vertically).

Information
For any questions, please contact:

Kenes Group Spain
Phone: +34 91 361 2600
E-mail: emchd2019-abs@kenes.com

Contact us

Send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt